Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 164

Sort by

Sort Order Select

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

Eduardo Edelman Saul, Jessie Xu, Casey Bermack, Cathrine Paras, Jared Henderson, Kristofer Jennings, Bryan Valcarcel, Dr. Mohammad Abdul-Jaber Abdulla, Luis Fayad, Hun Lee, Preetesh Jain, Ranjit Nair, Michael Wang, Swami Iyer, Christopher Flowers, Luis Malpica

Blood (2025) 146 (Supplement 1): 5422.

https://doi.org/10.1182/blood-2025-5422

Published: 2025

Journal Articles

PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis.

Lohitha Dhulipalla, Tapasya Raavi, Meghana Pattipati, Kai Wang, Monika Karki, Sihle Mabhida, Luis Malpica, Ranjit Nair, Luis Fayad, Neha Mehta-Shah, Ranjana Advani, Kerry Savage, Steven Horwitz, Maria Rodriguez, F. B. Hagemeister, Swami Iyer

Blood (2025) 146 (Supplement 1): 6299.

https://doi.org/10.1182/blood-2025-6299

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2025-5500

Published: 2025

Journal Articles

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Dai Chihara, Paolo Strati, Preetesh Jain, Luis Fayad, Frederick Hagemeister, Maria Rodriguez, Richard Davis, Michael Wang, Sattva Neelapu, Christopher Flowers, Jason Westin

Blood (2025) 146 (Supplement 1): 5369.

https://doi.org/10.1182/blood-2025-5369

Published: 2025

Journal Articles

Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome

Jillian Gunther, Auris Huen, Julia Dai, Swami Iyer, Carlos Torres-Cabala, Luis Fayad, Luis Malpica, Timothy Lin, Penny Fang, Susan Wu, Chelsea Pinnix, Jessie Xu, Ranjit Nair, Samer Srour, Rita Khouri, Jeremy Ramdial, Yago Nieto, Chitra Hosing, Bouthaina Dabaja

Blood (2025) 146 (Supplement 1): 3650.

https://doi.org/10.1182/blood-2025-3650

Published: 2025

Journal Articles

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Blood (2025) 146 (Supplement 1): 806.

https://doi.org/10.1182/blood-2025-806

Published: 2025

Journal Articles

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)

Blood (2025) 146 (Supplement 1): 5434.

https://doi.org/10.1182/blood-2025-5434

Published: 2025

Journal Articles

Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib.

Ranjit Nair, Sandra Lopez, Anita Aickareth, David Weaver, Qi Liu, Wendy Xiong, Luis Malpica, Luis Fayad, Jennifer Ramos, Yago Nieto, Auris Huen, Swami Iyer

Blood (2025) 146 (Supplement 1): 5432.

https://doi.org/10.1182/blood-2025-5432

Published: 2025

Journal Articles

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2025-3691

Published: 2025

Journal Articles

Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study

Hun Lee, Gregory Ravizzini, Jenna Wixom, Ayushi Chauhan, Luis Fayad, Ranjit Nair, Jason Westin, Jared Henderson, Eslam Aboismail, Christopher Flowers, Michael Wang, Luis Malpica Castillo

Blood (2025) 146 (Supplement 1): 153.

https://doi.org/10.1182/blood-2025-153

Published: 2025

Journal Articles

Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study

Paolo Strati, Lei Feng, Jason Westin, Ranjit Nair, Luis Fayad, Maria Alma Rodriguez, Dai Chihara, Luis Malpica, Jared Henderson, Mariana Gallardo, Mario L. Marques-Piubelli, Polina Turova, Aleksandr Zaitsev, Iris Wang, Christopher R. Flowers, Loretta J. Nastoupil, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 983.

https://doi.org/10.1182/blood-2023-180762

Published: 2023

Journal Articles

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 856.

https://doi.org/10.1182/blood-2023-180381

Published: 2023

Journal Articles

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2023-187903

Published: 2023

Journal Articles

A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy

Ajlan Al Zaki, Lei Feng, Jason Westin, Ranjit Nair, Luis Fayad, Grace Watson, Sherry Adkins, Elizabeth J. Shpall, Mario L. Marques-Piubelli, Jared Henderson, Loretta J. Nastoupil, Christopher R. Flowers, Sairah Ahmed, Sattva S. Neelapu, Paolo Strati

Blood (2023) 142 (Supplement 1): 3098.

https://doi.org/10.1182/blood-2023-179004

Published: 2023

Journal Articles

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Jason Westin, Ranjit Nair, Luis Fayad, Swami P. Iyer, Luis Malpica, Sattva S. Neelapu, Felipe Samaniego, Raphael Eric Steiner, Paolo Strati, Shivon Mathew, Donna Griffith, Loretta J. Nastoupil, Wirt Montinez, Maria Alma Rodriguez, Frederick Hagemeister, Lei Feng, Francisco Vega, Christopher R. Flowers, Sairah Ahmed

Blood (2023) 142 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2023-191123

Published: 2023

Journal Articles

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preetesh Jain, Hun Ju Lee, Jason Westin, Loretta J. Nastoupil, Luis Fayad, Ranjit Nair, Swami P. Iyer, Rashmi Kanagal-Shamanna, Ahmed Fetooh, Holly A Hill, Chi Young Ok, Wendy Chen, Onyeka Oriabure, Lei Feng, Guilin Tang, Francisco Vega, Maria Badillo, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2023-181312

Published: 2023

Journal Articles

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Blood (2023) 142 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2023-191096

Published: 2023

Journal Articles

Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Andrew Jallouk, Lei Feng, Mansoor Noorani, Kaberi Das, Raphael E Steiner, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Jason Westin, Luis Fayad, Dai Chihara, Luis Enrique Malpica Castillo, Swaminathan P. Iyer, Sairah Ahmed, Elizabeth J Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati

Blood (2022) 140 (Supplement 1): 10424–10426.

https://doi.org/10.1182/blood-2022-166783

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis.

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)

Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib.

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study

Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only